NANJING, China, June 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced the filing of its annual report on Form 20-F for the year ended December 31, 2008 with the Securities and Exchange Commission on June 18, 2009. The annual report can be accessed on the Company’s website at http://www.simcere.com under the investor relations section. The Company will provide a hard copy of its audited financial statements for the year ended December 31, 2008, free of charge, to its shareholders and ADS holders upon request.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
CONTACT: Investor and Media Contact: ir@simcere.com; In Nanjing: Frank
Zhao, Chief Financial Officer, Simcere Pharmaceutical Group at
+86-25-8556-6666 x8818; In the United States: Kate Tellier, Brunswick Group
LLC at +1-212-333-3810; In Beijing: Kejia Wu, Brunswick Group at
+86-10-6566-2256; In Hong Kong: Joseph Lo Chi-Lun, Brunswick Group at
+852-3512-5000
Web site: http://www.simcere.com/
